Project/Area Number |
22790715
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Circulatory organs internal medicine
|
Research Institution | University of Miyazaki |
Principal Investigator |
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 臨床心血管病態学 / バイオマーカー / 生理活性ペプチド / レニン・アンジオテンシン系 / プロアンジオテンシン-12 / 循環器疾患 / 腎臓疾患 / ラジオイムノアッセイ / レニン・アンジオテンシン / 高血圧 / 循環器・腎臓疾患 / 質量分析装置 |
Research Abstract |
I isolated and identified a new angiotensinogen-derived peptide from the human urine. Then, I made antiserum to use rabbits for this peptide. And I established assay system. So, I collected urine samples and measured of this peptide by radioimmunoassay. I found that urinary new peptide/creatinin ratio was significantly higher than the estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 group in other two groups (eGFR >90, 90-30 ml/min/1.73 m2). And, when compared with the protein urea plas in diabetes, the urinary new peptide/creatinin ratio was significantly higher than in protein urea minus group. In addition, urinary this peptide is associated renal derangement in patients with diabetic nephropathy. In addition, this peptide is abundant in a wide range of organs and tissues including the heart and kidney of human by immunohistochemistory.
|